Clinical evaluation of new quadruplet therapy for Helicobacter pylori eradication
GU Yong1, YANG Yan2, WANG Lan1, LI Na1, XI Zengqian1, and DUAN Wei1
1.Digestive System Department,Shaanxi Provincial Crops Hospital of Chinese People’s Armed Police Force, Xi’an Shaanxi 710054, China; .2.Xijing Hospital of Digestive Diseases,Fourth Military Medical University,Xi’an,710032,China
Abstract：Objective To compare the clinical efficacy and adverse events of three different therapies for Helicobacter pylori (H. pylori) eradication. Methods Four hundred and twenty H. pylori positive patients were randomly assigned into three groups in this open-label, prospective, controlled study. Group A patients received 14-day standard quadruplet therapy (esomeprazole plus colloidal bismuth pectin, amoxicillin and clarithromycin). Group B received 14-day new quadruplet therapy (esomeprazole plus colloidal bismuth pectin, amoxicillin and ring ciprofloxacin). Group C received 10-day sequential therapy (esomeprazole plus amoxicillin for 5 days, followed by esomeprazole plus ciprofloxacin and tinidazole for 5 days). H. pylori eradication rate, reinfection rates and adverse events were assessed at three months and six months after treatment. Results H. pylori eradication rates in group B, group C were significantly higher than in the group A (92.9%, 95.7% vs 85.0%, P<0.05). H. pylori reinfection rates were 10.1%, 6.2%, 7.5%, respectively, with no significant difference between the three groups,at three months after treatment. Six months after treatment, H. pylori reinfection rate in group A was 26.9%, which was significantly higher than in groups B, and C, with a 13.8% and 11.9%, respectively (P<0.05). The incidence rate of adverse events between the three groups was not significantly different. Conclusions Ciprofloxacin-based new quadruple therapy and 10-day sequential therapy are both efficient and safe, with a low reinfection rate and high patient compliance, and can be recommended as first-line anti-H. pylori therapy.
顾 勇，杨 艳，王 兰，李 娜，惠增骞，段 炜. 新四联根除幽门螺旋杆菌的临床对比研究[J]. 武警医学, 2016, 27(5): 493-496.
GU Yong, YANG Yan, WANG Lan, LI Na, XI Zengqian, and DUAN Wei. Clinical evaluation of new quadruplet therapy for Helicobacter pylori eradication. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(5): 493-496.
Strugatsky D,McNulty R,Munson K,et al.Structure of the proton-gated urea channel from the gastric pathogen Helicobacter pylori[J]. Nature ,2013,493(7431):255-258.
[2]
Fukamachi H, Mimata A,Tanaka I, et al. In vitro differentiation of Runx3-/- p53-/- gastric epithelial cells into intestinal type cells[J].Cancer Sci, 2008, 99(4):671-676.
[3]
Martinde Argila C, Boixeda D,Canton R,et al.High seroprevalence of Helicobacterpylori infection in coronary heart disease[J].Lancet,1995, 346(8970):310.
[4]
Gasbarrini A,Franceschi F,Tartaglione R,et al.Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori[J].Lancet,1998 ,352(9131):878.
[5]
Hirata Y,Ohmae T,Yanai A, et al.Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan[J].Int J Antimicrob Agents ,2012 ,39(4):352-355.
[6]
Tay CY,Windsor HM,Thirriot F, et al. Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations[J]. Aliment PharmacolTher, 2012,36(11-12):1076-1083.
[7]
IARC. schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994 [J] . IARC MonogrEvalCarcinog Risks Hum,1994,61:1-241.
[8]
Kokkola A, Sipponen P, Rautelin H, et al. The effect of Helicobacter pylori eradication on the natural course ofatrophic gastritis with dysplasia[J]. Alimentary Pharmacology and Therapeutics,2002,16:515-520.
[9]
Venerito M,Malfertheiner P. Preneoplastic Conditions in the Stomach: Always a Point of No Return[J].Dig Dis,2015,33(1):5-10.
[10]
Lee HJ,Kim JI,Cheung DY, et al.Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance[J]. J Infect Dis, 2013 ,208(7):1123-1130.
[11]
Zhang S,DesrosiersJ,Aponte-Pieras JR, et al.Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods[J].PLoS One,2014,9(4):e94974.
[12]
Liou JM, Chen CC,Chen MJ, et al .Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial[J]. Lancet, 2013, 381(9862):205-213.
[13]
Bago P1, Vcev A, Tomic M, et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial [J]. Wien Klin Wochenschr,2007,119(11-12):372-378.
[14]
Kwon AS, Park GC, Ryu SY, et al. Higher biofilm formation in multidrug-resistant clinical isolates of Staphylococcus aureus. [J]. Int J Antimicrob Agents, 2008, 32(1):33- 39.
2016, Vol. 27 
